[go: up one dir, main page]

DE60021497D1 - Human cyclic nucleotide-specific phosphodiesterase - Google Patents

Human cyclic nucleotide-specific phosphodiesterase

Info

Publication number
DE60021497D1
DE60021497D1 DE60021497T DE60021497T DE60021497D1 DE 60021497 D1 DE60021497 D1 DE 60021497D1 DE 60021497 T DE60021497 T DE 60021497T DE 60021497 T DE60021497 T DE 60021497T DE 60021497 D1 DE60021497 D1 DE 60021497D1
Authority
DE
Germany
Prior art keywords
cyclic nucleotide
specific phosphodiesterase
human cyclic
human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60021497T
Other languages
German (de)
Other versions
DE60021497T2 (en
Inventor
Mark David Fidock
Nicola Melanie Robas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Inc
Original Assignee
Pfizer Corp Belgium
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Inc filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of DE60021497D1 publication Critical patent/DE60021497D1/en
Publication of DE60021497T2 publication Critical patent/DE60021497T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Amino acid sequences and nucleotide sequences relating to PDEXV are described. In a preferred aspect, the amino acid sequence comprises the sequence presented as SEQ ID No. 1.
DE60021497T 1999-09-17 2000-09-14 Human cyclic nucleotide-specific phosphodiesterase Expired - Fee Related DE60021497T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922124.4A GB9922124D0 (en) 1999-09-17 1999-09-17 Phosphodiesterase enzymes
GB9922124 1999-09-17

Publications (2)

Publication Number Publication Date
DE60021497D1 true DE60021497D1 (en) 2005-09-01
DE60021497T2 DE60021497T2 (en) 2006-05-18

Family

ID=10861181

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60021497T Expired - Fee Related DE60021497T2 (en) 1999-09-17 2000-09-14 Human cyclic nucleotide-specific phosphodiesterase

Country Status (7)

Country Link
US (1) US7063971B2 (en)
EP (1) EP1085089B1 (en)
JP (1) JP2001136987A (en)
AT (1) ATE300613T1 (en)
DE (1) DE60021497T2 (en)
ES (1) ES2243208T3 (en)
GB (1) GB9922124D0 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1297115A2 (en) * 2000-06-26 2003-04-02 Bayer Aktiengesellschaft Regulation of human phosphodiesterase-like enzyme
EP1604033A2 (en) * 2002-11-08 2005-12-14 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a3 (pde11a3)
US7591302B1 (en) 2003-07-23 2009-09-22 Cooligy Inc. Pump and fan control concepts in a cooling system
US7616444B2 (en) * 2004-06-04 2009-11-10 Cooligy Inc. Gimballed attachment for multiple heat exchangers
CN101248087B (en) 2005-05-18 2012-09-26 埃博灵克斯股份有限公司 Improved nanobodies(tm) against tumor necrosis factor-alpha
EP3415535B1 (en) 2005-05-20 2020-12-09 Ablynx N.V. Improved nanobodies tm for the treatment of aggregation-mediated disorders
US20070114010A1 (en) * 2005-11-09 2007-05-24 Girish Upadhya Liquid cooling for backlit displays
JP2009527897A (en) * 2006-02-16 2009-07-30 クーリギー インコーポレイテッド Cooling system
US20070227709A1 (en) * 2006-03-30 2007-10-04 Girish Upadhya Multi device cooling
TW200813695A (en) 2006-03-30 2008-03-16 Cooligy Inc Integrated liquid to air conduction module
US20070227698A1 (en) * 2006-03-30 2007-10-04 Conway Bruce R Integrated fluid pump and radiator reservoir
EP2102244A2 (en) 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
US20100062004A1 (en) 2006-12-19 2010-03-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
WO2009068627A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
JP2011525476A (en) 2008-03-05 2011-09-22 アブリンクス エン．ヴェー． Novel antigen-binding dimer complex, its production method and use
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
HUE042919T2 (en) 2008-12-19 2019-07-29 Ablynx Nv Genetic immunization for producing immunoglobulins against cell-associated antigens such as p2x7, cxcr7 or cxcr4
US10005830B2 (en) 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
KR20130119990A (en) 2009-04-10 2013-11-01 아블린쓰 엔.브이. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
AU2010255638B2 (en) 2009-06-05 2014-10-16 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
AR083784A1 (en) 2010-11-08 2013-03-20 Novartis Ag LINK POLYPEPTIDES OF CHEMIOKIN RECEPTORS
EP2723772A1 (en) 2011-06-23 2014-04-30 Ablynx N.V. Immunoglobulin single variable domains directed against ige
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
AU2016360987A1 (en) 2015-11-27 2018-06-07 Ablynx Nv Polypeptides inhibiting CD40L
WO2018050833A1 (en) 2016-09-15 2018-03-22 Ablynx Nv Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
US11840569B2 (en) 2016-11-16 2023-12-12 Ablynx N.V. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
IL317858A (en) 2017-06-02 2025-02-01 Merck Patent Gmbh Polypeptides binding adamts5, mmp13 and aggrecan
JP7320457B2 (en) 2017-06-02 2023-08-03 アブリンクス エン．ヴェー． aggrecan-binding immunoglobulin
MX2019014448A (en) 2017-06-02 2020-02-10 Merck Patent Gmbh Mmp13 binding immunoglobulins.
CN111032695B (en) 2017-06-02 2024-06-25 默克专利股份有限公司 ADAMTS-binding immunoglobulin
TW202000238A (en) 2018-02-26 2020-01-01 比利時商艾伯林克斯公司 Improved nucleotide sequences encoding peptide linkers
CN115433733A (en) 2021-06-04 2022-12-06 生物岛实验室 Cyclic RNA (ribonucleic acid) Circ-ACE2 translated polypeptide and application thereof
CN114369162B (en) 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 Antibodies and uses thereof
WO2024012539A1 (en) 2022-07-14 2024-01-18 百奥泰生物制药股份有限公司 Anti-nectin-4 antibody and use thereof
TW202423965A (en) 2022-07-27 2024-06-16 比利時商艾伯霖克斯公司 Polypeptides binding to a specific epitope of the neonatal fc receptor
TW202440614A (en) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 Protein-based conjugation carriers
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
WO2025008537A1 (en) 2023-07-05 2025-01-09 Ablynx Nv Improved fcrn antagonists for treatment of igg-related diseases and disorders
WO2025051767A1 (en) 2023-09-04 2025-03-13 Sanofi Polypeptides for use in the treatment of glypican-3-expressing tumours
WO2025056575A1 (en) 2023-09-11 2025-03-20 Novo Nordisk A/S Anti il-6 domain antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386967B1 (en) * 1991-04-19 2010-05-26 The Board of Regents of the University of Washington DNA Encoding Mammalian phosphodiesterases
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US5798246A (en) * 1996-03-25 1998-08-25 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterase
EP0967284A1 (en) * 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
US6100037A (en) * 1999-01-07 2000-08-08 Incyte Pharmaceuticals, Inc. Human cyclic nucleotide PDEs

Also Published As

Publication number Publication date
EP1085089A3 (en) 2001-05-09
EP1085089A2 (en) 2001-03-21
US7063971B2 (en) 2006-06-20
ATE300613T1 (en) 2005-08-15
GB9922124D0 (en) 1999-11-17
US20040126863A1 (en) 2004-07-01
DE60021497T2 (en) 2006-05-18
JP2001136987A (en) 2001-05-22
EP1085089B1 (en) 2005-07-27
ES2243208T3 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
DE60021497D1 (en) Human cyclic nucleotide-specific phosphodiesterase
CY1106978T1 (en) PHOSPHOSESTERATION ENZYME
MXPA03002572A (en) Nucleotide sequences mediating male fertility and method of using same.
CY1106041T1 (en) BRAND NEW COLLECTOR
HK1154623A1 (en) Isolated luciferases and the use thereof
MXPA03006984A (en) Nucleotide sequence mediating male fertility and method of using same.
GB0020331D0 (en) Enzyme
NZ336360A (en) Printing on a substrate an outline and applying sufficient energy to the outline to weaken the outline
ATE353913T1 (en) NEW COLLECTINE
DK0919621T3 (en) Human TAK1 and DNA encoding therefore
EA199900893A1 (en) BACTERIAL PLASMIDES
WO2001029084A3 (en) Novel human proteins and polynucleotides encoding the same
BR0107799A (en) Wt1 interaction protein wtip
DE60021707D1 (en) BETA-PRIMEVEROSIDASE GEN
ECSP982465A (en) BACTERIAL PLASMIDS

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee